Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis

Journal of Autoimmunity

Volumn 12, Issue 1, 1999, Pages 35-42

  Chu, Cong Qiu ^a,b   Londei, Marco ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b TRUDEAU INSTITUTE   (United States)

Author keywords

Collagen type II peptides; Collagen induced arthritis; Nasal tolerance

Indexed keywords

COLLAGEN TYPE 2;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE ACTIVATION;

EID: 0033080994     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1998.0255     Document Type: Article

References (35)

1. Gammon G., Dunn K., Shastri N., Oki A., Wilbur S., Sercarz E.E. 1986. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. Nature 319: 413-415
2. Gammon G.M., Oki A., Shastri N., Sercarz E.E. 1986. Induction of tolerance to one determinant on a synthetic peptide does not affect the response to a second linked determinant. Implications for the mechanism of neonatal tolerance induction. J. Exp. Med. 164: 667-672
3. Forsthuber T., Yip H.C., Lehmann P.V. 1996. Induction of Th1 and Th2 immunity in neonatal mice. Science 271: 1728-1730
4. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. 1994. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265: 1237-1240
5. Weiner H.L. 1994. Oral tolerance. Proc. Natl. Acad. Sci. USA 91: 10762-10765
6. Miller A., Zhang Z.J., Sobel R.A., Al S.A., Weiner H.L. 1993. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. Intravenous tolerization. J. Neuroimmunol. 46: 73-82
7. Thompson H.S.G., Staines N.A. 1990. Could specific oral tolerance be a therapy for autoimmune disease? Immunol. Today 11: 396-399
8. Whitacre C.C., Gienapp I.E., Orosz C.G., Bitar D.M. 1991. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy J. Immunol. 147: 2155-2163
9. Trentham D.E., Dynesius T.R., Orav E.J., Combitchi D., Lorenzo C, Sewell K.L., Hafler D.A., Weiner H.L. 1993. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261: 1727-1730
10. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., Hafler D.A. 1993. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321-1324
11. Metzler B., Wraith D.C. 1993. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int. Immunol. 5: 1159-1165
12. Dick A.D., Cheng Y.E, McKinnon A., Liversidge J., Forrester J.V. 1993. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. Br. J. Ophthalmol. 77: 171-175
13. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., Kaufman D.L. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1561-1567
14. Hoyne G.F., O'Hehin R.E., Wraith D.C., Thomas W.R., Lamb J.R. 1993. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178: 1783-1788
15. Staines N.A., Harper N., Ward F.J., Malmstrom V., Holmdahl R., Bansal S. 1996. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103: 368-375
16. Myers L.K., Seyer J.M., Stuart J.M., Kang A.H. 1997. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 90: 161-164
17. Ranges G.E., Sriram S., Cooper S.M. 1985. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162: 1105-1110
18. Chu C.Q., Londei M. 1996. Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J. Immunol. 157: 2685-2689
19. Thompson H.S., Staines N.A. 1986. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. 64: 581-586
20. Khare S.D., Krco C.J., Griffiths M.M., Luthra H.S., David C.S. 1995. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J. Immunol. 155: 3653-3659
21. Williams R.O., Feldmann M., Maini R.N. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89: 9784-9788
22. Lambert L.E., Berling J.S., Thompson S.D., Harton J.A., Bishop G.A., Choi E. 1995. Polymorphism in the β chain of IAq versus IAp influences presentation of protein but not peptide antigens. Cell. Immunol. 165: 202-210
23. Jansson L., Olsson T., Hojeberg B., Holmdahl R. 1991. Chronic experimental autoimmune encephalomyelitis induced by the 89-101 myelin basic protein peptide in B10RIII (H-2r) mice. Eur. J. Immunol. 21: 693-699
24. Mauri C., Williams R.O., Walmsley M., Feldmann M. 1996. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 26: 1511-1518
25. Myers L.K., Stuart J.M., Seyer J.M., Kang A.H. 1989. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J. Exp. Med. 170: 1999-2010
26. Myers L.K., Terato K., Seyer J.M., Stuart J.M., Kang A.H. 1992. Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis. J. Immunol. 149: 1439-1443
27. Lambert L.E., Berling J.S. 1994. Structural requirements for recognition of a type II collagen peptide by murine T cell hybridomas. Cell. Immunol. 153: 178-183
28. Myers L.K., Roslonied E.F., Seyer J.M., Stuart J.M., Kang A.H. 1993. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J. Immunol. 150: 4652-4658
29. Brand D.D., Myers L.K., Terato K., Whittington K.B., Stuart J.M., Kang A.H., Rosloniec E.E 1994. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine α 1(II)-CB11 in H-2q mice. J. Immunol. 152: 3088-3097
30. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263: 1139-1143
31. Durie F.H., Foy T.M., Masters S.R., Laman J.D., Noelle R.J. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15: 406-411
32. Melamed D., Friedman A. 1994. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: Anergy in the absence of suppression. Eur. J. Immunol. 24: 1974-1981
33. Melamed D., Friedman A. 1993. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur. J. Immunol. 23: 935-942
34. Lakkis F.G., Konieczny B.T., Saleem S., Baddoura F.K., Linsley P.S., Alexander D.Z., Lowry R.P., Pearson T.C., Larsen C.P. 1997. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J. Immunol. 158: 2443-2448
35. Webb L.M., Walmsley M.J., Feldmann M. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2. Eur. J. Immunol. 26: 2320-2328